News | Podcasts | December 4, 2025
Diabetes Dialogue: Celebrating 2025 as The Year of the Incretin Therapy Author(s) Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES , Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES This special edition episode explores the advancements in incretin therapies that defined 2025.
The rise of GLP-1 receptor agonists across a multitude of specialties and into the public consciousness has been meteoric and while many specialties now marvel at the effects of the class, endocrinology has been...
November 16th, 2026 Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.
November 16th, 2026 Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.
November 12th, 2026 TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.
November 12th, 2026 Tom Martens, MD, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss CONNECT trial data on CGM in non-insulin-treated type 2 diabetes.
November 19th, 2026 Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.
November 17th, 2026 Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
November 15th, 2026 Hiddo Heerspink, PharmD, PhD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack finerenone’s FIND-CKD data in FSGS.
November 15th, 2026 Lesley Inker, MD, MS, joins Brendon Neuen, MBBS, PhD, to unpack GFR slope and hierarchical composite endpoints in glomerular disease trials.